Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1979 1
1980 2
1982 2
1983 1
1984 1
1985 2
1986 8
1987 4
1988 4
1989 7
1990 15
1991 7
1992 6
1993 8
1994 8
1995 10
1996 11
1997 7
1998 15
1999 10
2000 18
2001 5
2002 17
2003 20
2004 11
2005 11
2006 5
2007 8
2008 10
2009 12
2010 10
2011 8
2012 9
2013 4
2014 10
2015 7
2016 7
2017 5
2018 7
2019 5
2020 6
2021 7
2022 2
2023 5
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...Risk …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cypro …
A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS, Zhang JJY, Kirollos R, Santarius T, Nga VDW, Yeo TT. Lee KS, et al. Sci Rep. 2022 Feb 4;12(1):1942. doi: 10.1038/s41598-022-05773-z. Sci Rep. 2022. PMID: 35121790 Free PMC article.
The influence of exposure to hormonal treatments, particularly cyproterone acetate (CPA), has been posited to contribute to the growth of meningiomas. Given the widespread use of CPA, this systematic review and meta-analysis attempted to assess real-world evidence of the a …
The influence of exposure to hormonal treatments, particularly cyproterone acetate (CPA), has been posited to contribute to the growt …
Interventions for female pattern hair loss.
van Zuuren EJ, Fedorowicz Z, Schoones J. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628. doi: 10.1002/14651858.CD007628.pub4. Cochrane Database Syst Rev. 2016. PMID: 27225981 Free PMC article.
There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement in total hair count measured from baseline.Further randomised controlled trials of other widely-used treatments, such as spironolactone, fi …
There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article.
MAIN RESULTS: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel-containing COCs (pooled …
MAIN RESULTS: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospiren …
Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins.
Amiri M, Ramezani Tehrani F, Nahidi F, Kabir A, Azizi F, Carmina E. Amiri M, et al. Metabolism. 2017 Aug;73:22-35. doi: 10.1016/j.metabol.2017.05.001. Epub 2017 May 10. Metabolism. 2017. PMID: 28732568 Review.
In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. ...
In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment using cyproterone acetate (CA) o …
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Stegeman BH, et al. BMJ. 2013 Sep 12;347:f5298. doi: 10.1136/bmj.f5298. BMJ. 2013. PMID: 24030561 Free PMC article.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyprote …
Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial.
Angus LM, Leemaqz SY, Kasielska-Trojan AK, Mikołajczyk M, Doery JCG, Zajac JD, Cheung AS. Angus LM, et al. J Clin Endocrinol Metab. 2025 May 19;110(6):e1874-e1884. doi: 10.1210/clinem/dgae650. J Clin Endocrinol Metab. 2025. PMID: 39288020 Free PMC article. Clinical Trial.
CONTEXT: Transgender people with sex recorded male at birth desiring feminization commonly use cyproterone acetate or spironolactone as antiandrogens with estradiol, but the optimal antiandrogen is unclear. ...Cyproterone acetate was more likely to suppress serum te …
CONTEXT: Transgender people with sex recorded male at birth desiring feminization commonly use cyproterone acetate or spironolactone …
Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S. Burinkul S, et al. J Sex Med. 2021 Jul;18(7):1299-1307. doi: 10.1016/j.jsxm.2021.05.003. J Sex Med. 2021. PMID: 34274044 Clinical Trial.
Serious adverse effects observed in cyproterone acetate users were drug-induced liver injury and asymptomatic hyperprolactinemia. ...Anti-Andorgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial …
Serious adverse effects observed in cyproterone acetate users were drug-induced liver injury and asymptomatic hyperprolactinemia. ... …
Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.
Liao M, Li X, Zhang H, Zhou L, Shi L, Li W, Shen R, Peng G, Zhao H, Shao J, Wang X, Sun Z, Zheng H, Long M. Liao M, et al. Endocrine. 2024 Jan;83(1):227-241. doi: 10.1007/s12020-023-03487-4. Epub 2023 Aug 31. Endocrine. 2024. PMID: 37653215 Free PMC article. Clinical Trial.
This study aims to compare the therapeutic effectiveness of glucagon-like peptide-1 receptor agonist (GLP-1RA) + Metformin (Met) versus cyproterone acetate/ethinylestradiol (CPA/EE) + Met in overweight PCOS women and identify potential proteomic biomarkers of disease risk …
This study aims to compare the therapeutic effectiveness of glucagon-like peptide-1 receptor agonist (GLP-1RA) + Metformin (Met) versus c …
319 results